DENVER & TAMPA, Fla., Oct. 18, 2022 (GLOBE NEWSWIRE) — LMF Acquisition Opportunities, Inc. LMAO (LMAO), a special purpose entity sponsored by LM Funding America, Inc. LMFAand SeaStar Medical, Inc., a medical technology company developing proprietary solutions to reduce the impact of hyperinflammation on vital organs, announced today that LMAO shareholders at the special meeting of LMAO shareholders (the “Special Meeting”), the today, October 18, 2022.
More than 96% of the votes cast at the meeting voted to approve the business combination with SeaStar Medical. Holders of approximately 79% of the issued and outstanding shares of LMAO will vote at the special meeting.
The business combination is expected to close upon satisfaction of all closing conditions, at which time LMAO will be renamed “SeaStar Medical Holding Corporation” and the Company’s common stock and warrants are expected to trade on the Nasdaq under new ticker symbols “ICU” and “ICUCW” or.
The formal results of the vote will be included in a current report on Form 8-K filed by LMAO with the US Securities and Exchange Commission, which will be available at www.sec.gov.
About SeaStar Medical, Inc.
Denver-based SeaStar Medical, Inc. is a medical technology company focused on redefining how extracorporeal therapies can reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies draw on science and innovation to provide life-saving solutions to critically ill patients. It develops and commercializes extracorporeal therapies that target the effector cells that drive systemic inflammation, cause direct tissue damage and secrete a variety of pro-inflammatory cytokines that trigger and propagate imbalanced immune responses. For more information visit http://www.seastarmedical.com/ or visit us LinkedIn or
